New Program Expands Access to PacBio’s Highly Accurate Sequencing Systems by Providing Flexible Financing  

PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced PacBio Capital, a program that offers customers the ability to lease PacBio sequencing systems – Revio, Onso and Sequel IIe – easily and cost-effectively.

"Through PacBio Capital, we can expand our ability to reach customers and new markets," said Christian Henry, President and Chief Executive Officer of PacBio. "By making it possible to lease our game-changing sequencing systems, customers can conserve capital, and keep monthly payments down while continuing with their groundbreaking research."

PacBio Capital allows qualified customers to choose capital and operating lease structures with highly competitive rates and a six-month same as cash financing option. The streamlined credit and funding process can enable labs to fast-track their purchase of PacBio systems and allow more customers to benefit from the sub-$1,000 HiFi human genome on the recently released Revio system.

"It’s a win/win for PacBio and our current and future customers," said Jeff Eidel, Chief Commercial Officer at PacBio. "With PacBio Capital, we aim to get more systems into the hands of customers faster by offering them the flexibility to lease our products under the terms that work best for them."

PacBio has partnered with Mitsubishi HC Capital, a vendor finance company headquartered in Edina, Minn. with more than 30 years of experience in this sector to manage PacBio Capital in the U.S. Additional financing offerings are available globally through partners including Evosciences. The program is available now.

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.